Skip to main content
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. — Investor Relations & Filings

Ticker · PYXS ISIN · US7473241013 US Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2021-09-10 Capital/Financing Update
Country US United States of America
Listing US PYXS

About Pyxis Oncology, Inc.

https://pyxisoncology.com/

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a confidential draft registration statement submitted to the SEC on Form S-1 for Pyxis Oncology, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information typical of an S-1 filing, such as company overview, risk factors, use of proceeds, capitalization, management discussion, and financial statements index. Form S-1 is a registration statement used for securities offerings, which falls under capital raising activities. Therefore, this document is best classified as a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, confirming it is a substantive filing related to capital raising.
2021-09-10 English
Regulatory Filings 2021
Regulatory Filings
2021-08-18 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a law firm to the SEC staff regarding comments on a Draft Registration Statement on Form S-1 for Pyxis Oncology, Inc. It discusses revisions to the registration statement, clarifications on disclosures, and plans for filing exhibits. The Form S-1 is a registration statement used for initial public offerings (IPOs) and related securities offerings. This document is not the registration statement itself but a comment letter and response to SEC review comments. It is a regulatory filing related to the registration process but does not contain financial statements or report data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2021-08-04 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a confidential draft registration statement submitted to the SEC on Form S-1 for Pyxis Oncology, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes detailed prospectus information, risk factors, management discussion, financial statements, and underwriting details. This type of document is a capital markets filing related to fundraising and securities issuance, not a financial report, earnings release, or management report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, so it is not RPA or RNS. Hence, the correct classification is CAP with high confidence.
2021-08-04 English
Regulatory Filings 2021
Regulatory Filings
2021-07-16 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a confidential draft registration statement submitted to the U.S. Securities and Exchange Commission on Form S-1 for Pyxis Oncology, Inc. It is a registration statement under the Securities Act of 1933, indicating it is related to an initial public offering (IPO) or securities registration. The text includes a preliminary prospectus with detailed information about the company, its business, risk factors, management, and financial data. This type of document is a registration statement for securities offering, which falls under capital markets and financing activities rather than a financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, but a full registration statement draft.
2021-06-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.